The company informed that at a median of 17 months follow-up, the relapse rate in patients with low levels of HER2 expression treated with AE37 is half that of the same patient population in the control arm.
The primary endpoint of the study is to show a reduction in relapse rate in AE37 patients after 24 months follow-up.
Further, Antigen Express has concluded that all trials conducted to date have shown that AE37 is safe, well-tolerated, and induces the desired immune response.